keyword
MENU ▼
Read by QxMD icon Read
search

Folfox

keyword
https://www.readbyqxmd.com/read/28510798/total-laparoscopic-management-for-stage-iv-colorectal-cancer-requiring-multivisceral-resection
#1
Y Nancy You, Hironori Shiozaki, Jeffrey E Lee, Guillaume Passot, Claire Goumard, Masayuki Okuno, Thomas A Aloia, Cathy Eng, George Chang, Jean-Nicolas Vauthey, Claudius Conrad
BACKGROUND: Surgical resection of all sites of disease, in combination with effective systemic chemotherapy, offers the only potential chance for cure for patients with stage IV colorectal cancer (CRC). Coordinated multistage resection using a minimally invasive approach may provide optimal oncologic outcome while potentially offering the benefit of decreased morbidity. PATIENT: A 66-year-old women presented with transverse colon cancer and synchronous metastasis (CRLM) in segment IV involving the middle hepatic vein and main left portal pedicle, as well as the left adrenal gland...
May 16, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28502421/is-neoadjuvant-chemoradiotherapy-always-necessary-for-mid-high-local-advanced-rectal-cancer-a-comparative-analysis-after-propensity-score-matching
#2
Y Zhang, Y Sun, Z Xu, P Chi, X Lu
AIM: This study was aimed to compare perioperative and oncological outcomes of mid/high locally advanced midrectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (NCRT) vs. surgery alone, and to identify risk factors for local recurrence in mid/high LARC. METHOD: A total of 471 mid/high LARC patients treated with surgery alone or NCRT (50.4 Gy in 28 fractions) with concurrent FOLFOX/XELOX followed by TME in 6-8 weeks from 2008 to 2014 were matched 1:1 by using propensity score analysis...
May 4, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28458789/microsatellite-instability-in-medullary-carcinoma-of-the-colon
#3
Mario Martinotti, Fernando Cirillo, Marco Ungari, Giulia Tanzi, Giovanni Rolando, Antonio Tarasconi, Valerio Ranieri, Paolo Aulisa, Marco Vismarra, Massimo Rovatti, Monica Trombatore
Medullary carcinoma (MC) of the large intestine is a relatively new histological type of adenocarcinoma characterized by poor glandular differentiation and an intraepithelial lymphocytic infiltrate. MC can be associated to a defective mechanism for DNA mismatch repair, caused by the so-called microsatellite instability (MSI). We present the case of a 44 years old Caucasian woman, who referred to the Emergency Room with symptoms mimicking an acute appendicitis. Computed tomography and colonoscopy demonstrated an ulcerated and stenotic lesion of the caecum without signs of metastasis and peritoneal carcinosis...
March 24, 2017: Rare Tumors
https://www.readbyqxmd.com/read/28458715/clinical-effects-of-xihuang-pill-combined-with-chemotherapy-in-patients-with-advanced-colorectal-cancer
#4
Dan Yu, Guang Yu An
Objective. To investigate the therapeutic effects of Xihuang pill combined with chemotherapy on advanced colorectal cancer. Methods. Sixty-three patients with advanced colorectal cancer were divided into an experimental group (n = 32) and control group (n = 31). Patients in the experimental group were treated with traditional Chinese medicine combined with Western medicine (i.e., Xihuang pill with FOLFOX or FOLFIRI chemotherapy), and those in the control group were treated with FOLFOX or FOLFIRI chemotherapy alone...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28455965/prognosis-of-stage-iii-colorectal-carcinomas-with-folfox-adjuvant-chemotherapy-can-be-predicted-by-molecular-subtype
#5
Yujin Kwon, Minhee Park, Mi Jang, Seongju Yun, Won Kyu Kim, Sora Kim, Soonmyung Paik, Hyun Jung Lee, Sungpil Hong, Tae Il Kim, Byungsoh Min, Hoguen Kim
Individualizing adjuvant chemotherapy is important in patients with advanced colorectal cancers (CRCs), and the ability to identify molecular subtypes predictive of good prognosis for stage III CRCs after adjuvant chemotherapy could be highly beneficial. We performed microarray-based gene expression analysis on 101 fresh-frozen primary samples from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy and 35 matched non-neoplastic mucosal tissues. CRC samples were classified into four molecular subtypes using nonnegative matrix factorization, and for comparison, we also grouped CRC samples using the proposed consensus molecular subtypes (CMSs)...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28454330/high-bim-mrna-levels-are-associated-with-longer-survival-in-advanced-gastric-cancer
#6
Nandie Wu, Ying Huang, Zhengyun Zou, Ana Gimenez-Capitan, Lixia Yu, Wenjing Hu, Lijing Zhu, Xia Sun, Jose Javier Sanchez, Wenxian Guan, Baorui Liu, Rafael Rosell, Jia Wei
Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS)...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28449055/primary-tumor-sidedness-has-an-impact-on-prognosis-and-treatment-outcome-in-metastatic-colorectal-cancer-results-from-two-randomized-first-line-panitumumab-studies
#7
N Boeckx, R Koukakis, K Op de Beeck, C Rolfo, G Van Camp, S Siena, J Tabernero, J-Y Douillard, T André, M Peeters
Background: : Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. Material and methods: Data from two randomized first-line panitumumab trials were analyzed for treatment outcomes by primary tumor sidedness for RAS WT patients...
April 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28445892/feasibility-of-modified-folfox-in-elderly-patients-aged-%C3%A2-80-years-with-metastatic-gastric-cancer-or-colorectal-cancer
#8
Kyu-Hyoung Lim, Hui-Young Lee, Sung Bae Park, Seo-Young Song
OBJECTIVE: The aim of this study was to assess the feasibility of a modified FOLFOX regimen as first-line treatment in elderly patients with metastatic gastric cancer (GC) or colorectal cancer (CRC). METHODS: We included chemotherapy-naïve patients over 80 years old with metastatic GC or CRC in our study. From September 2008 to November 2014, 28 consecutive patients were enrolled and treated with modified FOLFOX. RESULTS: The study population consisted of an equal number of GC and CRC patients...
April 27, 2017: Oncology
https://www.readbyqxmd.com/read/28442526/morphoproteomic-guided-treatment-of-chemotherapy-resistant-colon-cancer-using-natural-based-therapies-a-case-study
#9
John Thomas Rogers, Robert E Brown, Jamie Jay Buryanek, Priya Weerasinghe
Colorectal cancer was estimated to have the fourth newest incident rate and to have the second highest death rate in 2015 according to the American Cancer Society. There were an estimated 132,700 new diagnoses of colorectal cancer made and approximately 69,000 deaths in 2015 attributing to this form of cancer. 5-fluorouracil (5-FU) or 5-FU with oxaliplatin (FOLFOX) continues to be the standard treatment protocol for patients presenting with colorectal cancer. However, treatment with FOLFOX and conventional chemotherapy has shown to lead to cancer recurrence and a number of toxic side effects...
March 2017: Annals of Clinical and Laboratory Science
https://www.readbyqxmd.com/read/28426267/a-phase-2-trial-of-single-agent-axitinib-as-maintenance-therapy-following-first-line-treatment-with-modified-folfox-bevacizumab-in-patients-with-metastatic-colorectal-cancer
#10
Johanna C Bendell, Mathew Joseph, Kirk Barnes, Mark Mainwaring, Dianna Shipley, Chandra Reddy, Laura Blakely, Ronald Blachly, Cassie M Lane, Chris Earwood, Michel Kuzur
This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axitinib maintenance after four cycles. The primary endpoint was progression-free survival (PFS). Seventy patients were enrolled. Common treatment-related toxicities were fatigue, nausea, diarrhea, and peripheral neuropathy during FOLFOX/bevacizumab treatment; and fatigue, hypertension, diarrhea, and peripheral neuropathy during axitinib treatment...
April 20, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28413395/a-case-of-advanced-gastric-cancer-with-para-aortic-lymph-node-metastasis-treated-with-preoperative-folfox-chemotherapy-followed-by-radical-subtotal-gastrectomy-and-d2-lymph-node-dissection
#11
Byoung Jo Suh
We report the case of a 73-year-old female who was diagnosed with advanced gastric cancer. Esophagogastroduodenoscopy was used to diagnose Borrmann type 3 advanced gastric cancer located at the gastric antrum. A biopsy revealed poorly differentiated adenocarcinoma. Abdominopelvic computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography-CT (FDG-PET-CT) scans demonstrated multiple lymph node metastases, including the para-aortic lymph nodes. Systemic chemotherapy with 5-fluoruracil (5-FU), oxaliplatin, and leucovorin (FOLFOX) was initiated...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28400427/circulating-dna-demonstrates-convergent-evolution-and-common-resistance-mechanisms-during-treatment-of-colorectal-cancer
#12
Alain R Thierry, Brice Pastor, Zhi-Qin Jiang, Anastasia Katsiampoura, Christine Parseghian, Jonathan M Loree, Michael J Overman, Cynthia Sanchez, Safia El Messaoudi, Marc Ychou, Scott Kopetz
Purpose: Liquid biopsies allow the tracking of clonal dynamics and detection of mutations during treatment. <p>Experimental design: We evaluated under blinded conditions the ability of cell free DNA (cfDNA) to detect RAS/BRAF mutations in the plasma of 42 metastatic colorectal cancer patients treated on a phase Ib/II trial of FOLFOX and dasatinib, with or without cetuximab. Results: Prior to treatment, sequencing of archival tissue detected mutations in 25/42 patients (60%), while the cfDNA assay detected mutations in 37/42 patients (88%)...
April 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28398406/-cetuximab-in-association-with-an-oxaliplatin-based-chemotherapy-as-first-line-treatment-of-metastatic-colorectal-cancer
#13
Fausto Petrelli, Antonio Ghidini, Alberto Zaniboni
The combination of cetuximab with an oxaliplatin-based chemotherapy is becoming a consolidate standard as first line treatment of metastatic colorectal cancer in RAS wild type patients either in the neoadjuvant setting or in the continuum of care of never resectable disease. Available evidence from clinical trials (not considering regimens containing capecitabine or bolus 5-Fu, as in the COIN and NORDIC study, respectively) has clearly outlined the safety and the efficacy of the combination of FOLFOX and cetuximab...
March 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28369355/recent-improvement-of-survival-prognosis-after-pulmonary-metastasectomy-and-advanced-chemotherapy-for-patients-with-colorectal-cancer
#14
Jun Nakajima, Tomohiko Iida, Sakae Okumura, Hirotoshi Horio, Hisao Asamura, Yuichi Ozeki, Norihiko Ikeda, Haruhisa Matsuguma, Masayuki Chida, Hajime Otsuka, Masafumi Kawamura
OBJECTIVES: New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis. METHODS: Using a large database, we conducted a retrospective, multi-institutional study to collect data of 1223 eligible patients from 26 institutions who had undergone pulmonary metastasectomy with curative intent...
May 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28367338/folfox-induced-takotsubo-cardiomyopathy-treated-with-impella-assist-device
#15
Swethika Sundaravel, Abdulah Alrifai, Mohamad Kabach, Waqas Ghumman
Chemotherapy induced cardiotoxicity is becoming increasingly prevalent with several new agents being used recently. The incidence of Takotsubo cardiomyopathy due to 5-fluorouracil based chemotherapeutic regimens like FOLFOX is not uncommon. It is also seen with platinum based chemotherapy. Most of these patients have reversible cardiotoxicity and the cardiac function recovers within a short period with supportive treatment. Here we have a patient who presented with cardiogenic shock after 5 days of receiving FOLFOX regimen for colorectal adenocarcinoma...
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28357089/chromothripsis-and-progression-free-survival-in-metastatic-colorectal-cancer
#16
Elina Skuja, Dagnija Kalniete, Miki Nakazawa-Miklasevica, Zanda Daneberga, Arnis Abolins, Gunta Purkalne, Edvins Miklasevics
Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases. The aim of this study was to evaluate the effect of chromothripsis and total breakpoint count (breakpoint instability index) on progression-free survival (PFS). A total of 19 patients with metastatic CRC (mCRC) receiving FOLFOX first-line palliative chemotherapy between August, 2011 and October, 2012 were selected for this study...
February 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28356954/multicenter-phase-ii-study-of-infusional-5-fluorouracil-5-fu-leucovorin-and-oxaliplatin-plus-biweekly-cetuximab-as-first-line-treatment-in-patients-with-metastatic-colorectal-cancer-celine-trial
#17
Masanori Kotake, Toru Aoyama, Yoshinori Munemoto, Kenji Doden, Masato Kataoka, Kenji Kobayashi, Genichi Nishimura, Hidehito Fujita, Keishi Nakamura, Akira Takehara, Chihiro Tanaka, Junichi Sakamoto, Naoki Nagata, Koji Oba, Ken Kondo
The current phase II study investigated the efficacy and safety of biweekly cetuximab combined with standard oxaliplatin-based chemotherapy [infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX-6)] in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Sixty patients with a median age of 64 years (range, 38-82 syears) received a biweekly intravenous infusion of cetuximab (500 mg/m(2) on day 1) followed by FOLFOX-6 (2-hour oxaliplatin 85 mg/m(2) infusion on day 1 in tandem with a 2-h leucovorin 200 mg/m(2) infusion on days 1 and 2, and 5-FU as a 400 mg/m(2) bolus followed by a 46-hour 2,400 mg/m(2) infusion on days 1-3)...
February 2017: Oncology Letters
https://www.readbyqxmd.com/read/28328969/oral-tegafur-uracil-as-metronomic-therapy-following-intravenous-folfox-for-stage-iii-colon-cancer
#18
Wen-Yen Huang, Ching-Liang Ho, Chia-Cheng Lee, Cheng-Wen Hsiao, Chang-Chieh Wu, Shu-Wen Jao, Jen-Fu Yang, Cheng-Hsiang Lo, Jia-Hong Chen
The purpose of this study was to estimate the impact of metronomic therapy with oral tegafur-uracil (UFUR) following an intravenous FOLFOX regimen as surgical adjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of stage III colon cancer patients. From the retrospective database of patients who underwent a surgical resection for colorectal cancer at the Tri-Service General Hospital from October 2008 through December 2014, stage III colon carcinomas treated with radical R0 resection were reviewed...
2017: PloS One
https://www.readbyqxmd.com/read/28328812/overall-survival-of-patients-with-kras-wild-type-tumor-treated-with-folfox-forfiri%C3%A2-cetuximab-as-the-first-line-treatment-for-metastatic-colorectal-cancer-a-meta-analysis
#19
REVIEW
Ya-Fan Yang, Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang
The addition of cetuximab to FOLFIRI or FOLFOX as the first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated systematic meta-analysis was undertaken to determine the efficacy of cetuximab plus FOLFIRI or FOLFOX.Major databases were searched to identify RCTs investigating wild-type KRAS mCRC after the first-line treatment, and treatment with FOLFOX/FORFIRI ± cetuximab was compared...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28301974/folfox-and-intensified-split-course-chemoradiation-as-initial-treatment-for-rectal-cancer-with-synchronous-metastases
#20
T Bird, M Michael, M Bressel, J Chu, S Chander, P Cooray, J McKendrick, M Jefford, A Heriot, M Steel, T Leong, S Ngan
BACKGROUND: Optimal initial management of rectal carcinoma with synchronous metastases (RCSM) is controversial - both for patients being treated with curative and palliative intent. This study aims to evaluate the use of an upfront treatment strategy combining FOLFOX chemotherapy with split-course pelvic chemoradiation (FOLFOX + CRT) for patients with RCSM. MATERIAL AND METHODS: An analysis of all patients who commenced treatment with FOLFOX + CRT at our institutions between January 2009 and June 2014 was performed...
March 16, 2017: Acta Oncologica
keyword
keyword
2273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"